Stock Markets
Insperity appoints new independent director
HOUSTON – Insperity, Inc. (NYSE: NYSE:), a provider of HR and business performance solutions, has announced the appointment of Phil Wilmington as a new independent director to its board. Wilmington, who recently retired as Vice Chairman of Workday (NASDAQ:), Inc., brings a wealth of experience from the HR services and software sectors to the role.
Wilmington’s appointment as a Class I director includes his service on the Compensation Committee, with a term set to expire at the annual stockholders meeting in 2026. His career has spanned executive leadership positions at PeopleSoft, CEO of OutlookSoft, and President and COO of Tidemark Systems, Inc., contributing to his reputation for fostering growth and innovation in the industry.
“I am honored to serve in this important role and bring additional insights and guidance based on my experience at Workday and other high-growth companies,” said Wilmington. “I look forward to working with my new board colleagues to bring continued growth and success to the businesses Insperity serves.”
Paul J. Sarvadi, chairman and CEO of Insperity, expressed confidence that Wilmington’s expertise, particularly his strategic partnership experience with Workday, will provide invaluable insight to advance Insperity’s mission of serving America’s small and medium-sized businesses.
Insperity, established in 1986, has been committed to helping businesses succeed, which in turn contributes to community prosperity. The company offers a comprehensive suite of HR solutions and has reported 2023 revenues of $6.5 billion. With over 90 locations across the United States, Insperity continues to impact numerous businesses and communities.
This expansion of the board reflects Insperity’s ongoing strategy for growth through innovation and superior offerings. The information regarding Wilmington’s appointment is based on a press release statement from Insperity, Inc.
InvestingPro Insights
As Insperity, Inc. (NYSE: NSP) welcomes Phil Wilmington to its board, the company’s financial health and market performance remain a key interest for investors. With a market cap of approximately $3.88 billion USD, Insperity stands as a significant player in the HR and business performance solutions sector.
The company’s commitment to innovation and growth is further underscored by its strong financial position, as highlighted by an InvestingPro Tip that notes Insperity holds more cash than debt on its balance sheet, providing a solid foundation for strategic initiatives and potential market maneuvers.
Another noteworthy InvestingPro Tip is Insperity’s track record of maintaining dividend payments for 20 consecutive years, which could be particularly appealing to income-focused investors. This consistency in rewarding shareholders is complemented by a dividend yield of 2.21% as of the latest data, and a notable dividend growth of 9.62% over the last twelve months as of Q1 2024.
While Insperity’s Price / Book multiple stands at a high 27.71, reflecting a premium valuation, this could be indicative of the market’s confidence in the company’s assets and future prospects. Moreover, analysts predict profitability for the current year, aligning with the company’s profitable performance over the last twelve months. With these insights, investors can gauge the company’s value proposition in the context of its industry and historical performance.
For those interested in a deeper dive into Insperity’s financial metrics and additional strategic tips, there are more InvestingPro Tips available at https://www.investing.com/pro/NSP. To enhance your investing strategy, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro, where you can find a total of 5 additional tips to inform your investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Stock Markets
S&P 500 hovers near record high as Trump says he’ll demand lower interest rates
Investing.com – The S&P 500 remained close to record highs Thursday as investors digested more corporate earnings and remarks from President Donald Trump at Davos in which he said he would demand interest rates be lowered.
At 12:47 ET (17:47 GMT), the rose 303 points, or 0.7%, while the index was 0.2% higher, and the dropped 0.3%.
Trump says he’ll demand Fed drops interest rates at Davos
Trump delivered a speech remotely to the World Economic Conference in Davos, Switzerland, touching on range of topics including interest rates, the US-China trade relationship, and domestic energy policy.
On interest rates, Trump said he would
“demand that interest rates drop immediately, and likewise they should be dropping all over the world.”
The remarks come ahead of the Fed meeting next week, with many on Wall Street expecting the central bank to hold rates steady,
The rate sensitive 2-year Treasury was largely unchanged, however, as he Fed like many other world central banks is independent.
The president did, however, pressure oil prices after saying he would ask Saudi Arabia to lower the price of oil and he reiterated a pledge to accelerate U.S. energy production.
American Airlines slumps, EA falls on guidance cut; Ge Aerospace shines
The quarterly corporate earnings season continues Thursday, with more senior companies releasing their results.
GE Aerospace (NYSE:) stock rose 7% after the aircraft engine supplier forecast a stronger full-year profit as demand for its high-margin parts and services got a boost from airlines flying older jets to sidestep a persistent shortage of new aircraft.
American Airlines (NASDAQ:) stock slumped 8% after the carrier’s first-quarter earnings outlook on Thursday fell short of expectations, forecasting an adjusted loss per share of 20 cents to 40 cents for the first three months of 2025, breaking from a more upbeat outlook from its rivals.
Electronic Arts (NASDAQ:) slumped 17% after the video game maker slashed its guidance for net bookings due to sluggish performance of its soccer titles.
“The drastic cut to Global Football’s near-term outlook does not provide a hard reset that investors looked for. Relative to a Battlefield delay, declines in Global Football are more alarming,” Oppenheimer said in a note.
Knight-Swift Transportation (NYSE:) stock rose 4% after fourth-quarter results showed improved operating margins, while Alaska Air (NYSE:) gained 4% after fourth-quarter results topped estimates on the top and bottom lines.
Labor market remains solid
Data released earlier Thursday showed that the number of Americans filing rose marginally last week, suggesting that solid job growth likely continued in January.
Initial claims for state unemployment benefits increased 6,000 to a seasonally adjusted 223,000 for the week ended Jan. 18.
However, freezing temperatures that have gripped large parts of the country and fires in Los Angeles could boost claims in the coming weeks.
(Peter Nurse, Ayushman Ojha contributed to this article.)
Stock Markets
GenSight Biologics Reports End-of-Year Cash Position and Provides Business Update
- Capital increases in late 2024 provide sufficient working capital until expected resumption of early access program in February.
- Review of LUMEVOQ ® dossier ongoing, following submission of responses to questions from the ANSM.
PARIS–(BUSINESS WIRE)–Regulatory News:
GenSight Biologics (“GenSight Biologics” or the “Company“) ( Euronext (EPA:): SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of December 31, 2024, and provided a business update.
“Our recent bridge financing operations have provided us with operational flexibility as we await regulatory clearance for the resumption of our early access program, noted Jan Eryk Umiastowski, Chief Financial Officer of GenSight Biologics. We remain focused on prudent cash management while working closely with ANSM to restart our program. The potential restart of the early access program represents an important milestone that would significantly strengthen our financial position and support our continued development efforts.“
Cash Position as of December 31, 2024
GenSight Biologics’ cash and cash equivalents totaled €2.5 million as of December 31, 2024, compared to €3.4 million on September 30, 2024.
The Company completed successful offerings in November and December 2024, through capital increases for gross amounts of approximately €2.8 million and €1.5 million, respectively, reserved to specialized investors. GenSight continues to work on optimizing cash management while ensuring a sustainable future.
To date, the Company does not have sufficient net working capital to meet its obligations over the next 12 months but only until late February 2025 when the first payments in connection with the potential resumption of the early access program (Autorisation d’Accès Compassionnel or AAC) are expected. With the potential indemnities generated by the resumption of AAC, the Company anticipates that it would have sufficient net working capital to meet its obligations over the next 12 months.
In November 2026, the Company will have to pay the annual rebates on the 2025 AAC program which will amount to around 50% of the AAC indemnities generated over the year. Consequently, the Company may need to seek other sources of debt or equity financing or achieve partnering or M&A opportunities, in order to supplement its working capital requirements and fund its operating expenses before the second half of 2026.
Regulatory Update
The French medicines safety agency ANSM (Agence Nationale de Sécurité des Médicaments et des produits de santé) is continuing its review of the LUMEVOQ ® quality dossier LUMEVOQ ® following the submission, on January 10, of the Company’s responses to the questions received from the agency in late December. GenSight teams, along with those of the treating center 15-20 National Hospital, are mobilized to act quickly on next steps once the ANSM’s green light is received.
Preparations for the new Phase III trial RECOVER and the planned submission to the UK’s MHRA are ongoing.
Number of outstanding shares
As of December 31, 2024, the Company’s share capital is composed of 124,774,445 shares.
Financial Calendar 2025
The Company’s financial calendar for 2025 is as follows:
Information | Date |
2024 Full-Year Financial Update and Statements | March 19, 2025 |
2025 Q1 Cash Position | April 7, 2025 |
Annual General Meeting | May 12, 2025 |
2025 Q2 Cash Position | July 8, 2025 |
2025 Half-Year Financial Update and Statements | September 19, 2025 |
2025 Q3 Cash Position | October 7, 2025 |
2025 Q4 Cash Position | January 8, 2026 |
This financial calendar is provided for information only and may be subject to changes. The Company’s updated financial calendar is available on the corporate website.
About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, LUMEVOQ ® (GS010; lenadogene nolparvovec), is an investigational compound and has not been registered in any country at this stage; a marketing authorization application is currently under review by the EMA for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding product development prospects and financial projections. These statements do not constitute guarantees of future performance and involve risks and uncertainties. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in GenSight Biologics’ regulatory filings with the French Autorité des Marchés Financiers. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, GenSight Biologics undertakes no obligation to update or revise the information contained in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250123773001/en/
GenSight Biologics
Chief Financial Officer
Jan Eryk Umiastowski
jeumiastowski@gensight-biologics.com
LifeSci Advisors
Investor Relations
Guillaume van Renterghem
gvanrenterghem@lifesciadvisors.com
+41 (0)76 735 01 31
Source: GenSight Biologics
Stock Markets
UK teenager jailed for minimum of 52 years for Southport girls’ murders
By Sam Tobin and Michael Holden
LONDON (Reuters) – A British teenager who killed three young girls at a Taylor Swift-themed dance event was jailed for at least 52 years on Thursday, for an attack Prime Minister Keir Starmer called one of the most harrowing moments in Britain’s history.
Axel Rudakubana, 18, admitted killing the girls and stabbing 10 others last July in the northern English town of Southport, an atrocity that shocked Britain and was followed by days of nationwide rioting.
Prosecutor Deanna Heer told Liverpool Crown Court that Rudakubana was obsessed with violence and genocide, and two of his victims suffered such terrible injuries they were “difficult to explain as anything other than sadistic in nature”.
Judge Julian Goose said Rudakubana should serve a minimum of 52 years. He said he could not impose a full life sentence as Rudakubana was 17 when the attack took place but he was unlikely ever to be released.
Twice during Thursday’s hearing, Rudakubana was removed from the dock after shouting he was unwell. He refused to return to court to hear his sentence.
The court was shown harrowing video footage of screaming girls fleeing the building. One bloodied girl collapsed outside, provoking gasps and sobs from the court’s public gallery.
“He targeted us because we were women and girls, vulnerable and easy prey,” Leanne Lucas, 36, the yoga teacher who organised the event and was stabbed five times, told the court.
Bebe King, six, Elsie Dot Stancombe, seven, and Alice Dasilva Aguiar, nine, were killed. They were among 26 children attending the summer vacation event.
Two suffered at least 85 and 122 sharp force injuries Heer said, saying it appeared he had tried to decapitate one of them.
After his arrest, Rudakubana told police: “I’m glad those kids are dead, it makes me happy.”
Images and documents found on a computer at his home showed a long obsession with violence, killing and genocide, Heer said.
Rudakubana also admitted possessing an al Qaeda training manual and producing ricin, a deadly poison which the judge said it was likely the teenager would have used.
MURDERS NOT CONSIDERED TERRORISM
Heer said the murders were not considered terrorism as Rudakubana was not inspired by any particular political or religious ideology. Material mocking religions including Islam, Judaism and Christianity had been found on his devices.
“It is not possible to identify any particular terrorist cause,” Heer said. “Rather, the evidence suggests that the defendant’s purpose was the commission of mass murder as an end in itself.”
Rudakubana had been diagnosed with autism but his lawyer, Stan Reiz, said he did not have a mental disorder that explained his actions and there was little he could offer in mitigation for “such wickedness”.
Heer said Rudakubana had in 2019 contacted a helpline for children and asked: “What should I do if I want to kill somebody?”
Soon afterwards, he was expelled from school after admitting bringing in a knife 10 times, and was arrested with a knife in his backpack after returning and attacking a pupil with a hockey stick, Heer said.
Rudakubana had been referred to a counter-radicalisation scheme, Prevent, after researching school shootings, uploading images of late Libyan leader Muammar Gaddafi to Instagram and researching an attack in London, but no action was taken.
The government has ordered a public inquiry, saying there were grave questions to answer.
“After one of the most harrowing moments in our country’s history we owe it to these innocent young girls and all those affected to deliver the change that they deserve,” Starmer said.
- Forex3 years ago
Forex Today: the dollar is gaining strength amid gloomy sentiment at the start of the Fed’s week
- Forex2 years ago
How is the Australian dollar doing today?
- Forex2 years ago
Unbiased review of Pocket Option broker
- Forex2 years ago
Dollar to pound sterling exchange rate today: Pound plummeted to its lowest since 1985
- Cryptocurrency2 years ago
What happened in the crypto market – current events today
- World2 years ago
Why are modern video games an art form?
- Commodities2 years ago
Copper continues to fall in price on expectations of lower demand in China
- Forex2 years ago
The dollar is down again against major world currencies